Hepatic impairment No dose adjustment is required in individuals with gentle or moderate (Kid-Pugh A or B) hepatic impairment (see part 5.2). Exposure to midostaurin and its Energetic metabolite CGP62221 is considerably decreased in clients with intense hepatic impairment than that in clients with o